pharmaceutical investing Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
pharmaceutical investing Johnson & Johnson presents new IMAAVY® data at European Academy of Neurology 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
pharmaceutical investing Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
New TALVEY® plus DARZALEX FASPRO® data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
IMAAVY® demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia , an autoantibody-driven disease with no FDA-approved therapies
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus disease activity in a Phase 2 study
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
RYBREVANT FASPRO pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
RYBREVANT® plus LAZCLUZE® demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
FDA approves label expansion, cementing TREMFYA® as the only IL?23 inhibitor proven to help stop further joint damage
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave C2 Aero Coronary IVL Catheter
Government approvals secured for the use of Galidesivir as a treatment for Bundibugyo Ebola epidemic in Africa
Alvopetro Announces June Sales Volumes, an Operational Update and Quarterly Natural Gas Pricing Update
